AIMS: To investigate the immunocytochemical expression of the tissue specific transcription factor-1 (TTF-1) on cytological specimens of small cell lung carcinoma (SCLC) and to establish its value in the cytological diagnosis of lung cancer. METHODS: For each case, the diagnosis was made on cytological specimens and confirmed on subsequent bronchial biopsy specimens. TTF-1 was detected immunocytochemically using the avidinbiotin complex technique with a rabbit antiserum. Expression of TTF-1 was evaluated in 41 cases of SCLC and 17 cases of non-small cell carcinoma (NSCC). The latter were subdivided into eight cases of adenocarcinomas and nine cases of squamous cell carcinomas (SCC). RESULTS: Positive nuclear immunoreactivity to TTF-1 was identified in 38 (92.7%) of the 41 cases of SCLC, in five (62.5%) of eight cases of adenocarcinoma, and one (11%) of nine cases of SCC. A significant difference was observed between the two main groups, SCLC and NSCC. A comparison between SCLC and adenocarcinoma and SCC showed that TTF-1 expression was significantly different. TTF-1 immunoreactivity was not detected in the inflammatory cells of the same cases. CONCLUSIONS: TTF-1 is strictly associated with SCLC; it was weakly expressed in the various subtypes of NSCC. Although TTF-1 is not specific for SCLC, it can be used to highlight neoplastic cells to good effect when a large inflammatory component is present, and to differentiate SCLC from lymphoid infiltrates.
AIMS: To investigate the immunocytochemical expression of the tissue specific transcription factor-1 (TTF-1) on cytological specimens of small cell lung carcinoma (SCLC) and to establish its value in the cytological diagnosis of lung cancer. METHODS: For each case, the diagnosis was made on cytological specimens and confirmed on subsequent bronchial biopsy specimens. TTF-1 was detected immunocytochemically using the avidinbiotin complex technique with a rabbit antiserum. Expression of TTF-1 was evaluated in 41 cases of SCLC and 17 cases of non-small cell carcinoma (NSCC). The latter were subdivided into eight cases of adenocarcinomas and nine cases of squamous cell carcinomas (SCC). RESULTS: Positive nuclear immunoreactivity to TTF-1 was identified in 38 (92.7%) of the 41 cases of SCLC, in five (62.5%) of eight cases of adenocarcinoma, and one (11%) of nine cases of SCC. A significant difference was observed between the two main groups, SCLC and NSCC. A comparison between SCLC and adenocarcinoma and SCC showed that TTF-1 expression was significantly different. TTF-1 immunoreactivity was not detected in the inflammatory cells of the same cases. CONCLUSIONS:TTF-1 is strictly associated with SCLC; it was weakly expressed in the various subtypes of NSCC. Although TTF-1 is not specific for SCLC, it can be used to highlight neoplastic cells to good effect when a large inflammatory component is present, and to differentiate SCLC from lymphoid infiltrates.
Authors: M C Perry; W L Eaton; K J Propert; J H Ware; B Zimmer; A P Chahinian; A Skarin; R W Carey; H Kreisman; C Faulkner Journal: N Engl J Med Date: 1987-04-09 Impact factor: 91.245
Authors: P A Bejarano; R P Baughman; P W Biddinger; M A Miller; C Fenoglio-Preiser; B al-Kafaji; R Di Lauro; J A Whitsett Journal: Mod Pathol Date: 1996-04 Impact factor: 7.842
Authors: Nicolle M Linnerth; Megan D Siwicky; Craig I Campbell; Katrina L M Watson; James J Petrik; Jeffrey A Whitsett; Roger A Moorehead Journal: Neoplasia Date: 2009-07 Impact factor: 5.715
Authors: David S Hsu; Chaitanya R Acharya; Bala S Balakumaran; Richard F Riedel; Mickey K Kim; Marvaretta Stevenson; Sascha Tuchman; Sayan Mukherjee; William Barry; Holly K Dressman; Joseph R Nevins; Scott Powers; David Mu; Anil Potti Journal: Proc Natl Acad Sci U S A Date: 2009-03-11 Impact factor: 11.205
Authors: Jude Kendall; Qing Liu; Amy Bakleh; Alex Krasnitz; Ken C Q Nguyen; B Lakshmi; William L Gerald; Scott Powers; David Mu Journal: Proc Natl Acad Sci U S A Date: 2007-10-09 Impact factor: 11.205